Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1993-02-02
1994-10-25
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514171, 514182, 514914, 514922, A61K 3156, A61K 3133
Patent
active
053589432
ABSTRACT:
Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortisol. The tetrahydrocortisol serves to substantially prevent any significant increases in intraocular pressure which might otherwise be experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortisol to a patient receiving such therapy.
REFERENCES:
patent: 3449494 (1969-06-01), Lerner
patent: 3474168 (1969-10-01), Schayer
patent: 4383992 (1983-05-01), Lipari
patent: 4617299 (1986-10-01), Knepper
patent: 4686214 (1987-08-01), Boltralik
patent: 4863912 (1989-09-01), Southren
patent: 4945089 (1990-07-01), Clark
Cantrill, et al., "Comparison of In Vitro Potency of Corticosteroids with Ability to Raise Intraocular Pressure", American Journal of Ophthalmology, vol. 79, pp. 1012-1016 (1975).
Kitazawa, "Increased Intraocular Pressure Induced by Corticosteroids", American Journal of Ophthalmology, vol. 82, pp. 492-495 (1976).
The Merck Index, Tenth Edition (1983).
Meyer, et al., "Influence of Norethynodrel with Mestranol on Intraocular Pressure in Glaucoma", Arch Ophthal., vol. 75, pp. 771-773 (1966).
Mindel, et al., "Comparative Ocular Pressure Elevation by Medrysone, Flourometholone, and Dexamethasone Phosphate", Archives of Ophthalmology, vol. 98, pp. 1577-1578 (1980).
Southren, A. Louis, et al., "Intraocular Hypotensive Effect of a Topically Applied Cortisol Metabolite: 3.alpha., 5.beta.-Tetrahydrocortisol", Investigative Ophthalmology & Visual Science, vol. 28, pp. 901-903 (May 1987).
Treister, et al., "Intraocular Pressure and Outflow Facility", Arch Ophthal., vol. 83, pp. 311-318 (1970).
Medline Abstract 87193644 (1987), Southren, et al.
Danhaive, et al., "Binding of Glucocorticoid Antagonists to Androgen and Glucocorticoild Hormone Receptors in Rat Skeletal Muscle", J. steroid Biochem., vol. 24, No. 2, pp. 481-487, 1986.
Clark Abbot F.
Southren Aaron L.
Arno James A.
Brown Gregg C.
Fay Zohreh
LandOfFree
Use of tetrahydrocortisol to prevent elevations in intraocular p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of tetrahydrocortisol to prevent elevations in intraocular p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tetrahydrocortisol to prevent elevations in intraocular p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-135513